(KIDS) Orthopediatrics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68752L1008

Implants, Plates, Screws, Braces, Spine

Stock: Health Care Supplies
Age 8.3y
MCap 454m
Avg Vol 132K (2.42M USD)
Beta 1.007
Volatility 48.37%

EPS (Earnings per Share)

EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2020-12": -0.73, "2021-03": -0.47, "2021-06": -0.19, "2021-09": -0.11, "2021-12": -0.24, "2022-03": -0.47, "2022-06": -0.02, "2022-09": -0.07, "2022-12": -0.35, "2023-03": -0.3, "2023-06": -0.13, "2023-09": -0.2, "2023-12": -0.29, "2024-03": -0.34, "2024-06": -0.26, "2024-09": -0.34, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24,
EPS CAGR: 0.00%
EPS Trend: -11.1%
Last SUE: 0.09
Qual. Beats: 0

Revenue

Revenue of KIDS over the last years for every Quarter: 2020-12: 18.924, 2021-03: 21.462, 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25,
Rev. CAGR: 27.25%
Rev. Trend: 95.3%
Last SUE: -0.91
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 48.4%
Value at Risk 5%th 75.3%
Relative Tail Risk -5.34%
Reward TTM
Sharpe Ratio -0.71
Alpha -49.59
CAGR/Max DD -0.39
Character TTM
Hurst Exponent 0.453
Beta 1.007
Beta Downside 1.192
Drawdowns 3y
Max DD 68.64%
Mean DD 43.79%
Median DD 47.59%

Description: KIDS Orthopediatrics December 27, 2025

OrthoPediatrics Corp. (NASDAQ: KIDS) designs, develops, and markets a full suite of pediatric-specific orthopedic implants, instruments, and braces for trauma, deformity correction, scoliosis, and sports-medicine applications. Its product portfolio includes the PediLoc and PediPlates systems, telescopic intramedullary nails (e.g., Fassier-Duval), growth-modulation devices (GIRO), and specialty braces such as the Boston Brace 3D, serving surgeons and caregivers in the United States and abroad.

Key market indicators suggest upside potential: the U.S. pediatric orthopedic device market is projected to grow at a 6-7% CAGR through 2028, driven by rising rates of childhood sports injuries and earlier detection of spinal deformities. OrthoPediatrics reported FY 2024 revenue of $84 million, up ~14% YoY, and its gross margin expanded to 68% after a cost-efficiency initiative. The company’s cash-burn has fallen to $9 million per quarter, giving it >12 months of runway without additional financing.

If you want a concise, data-rich view of KIDS’s valuation and risk profile, the ValueRay platform provides a quick-look dashboard that can help you assess whether the stock aligns with your risk-return objectives.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -45.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA 4.54 > 1.0
NWC/Revenue: 93.50% < 20% (prev 112.7%; Δ -19.16% < -1%)
CFO/TA -0.04 > 3% & CFO -19.2m > Net Income -45.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.40 > 1.5 & < 3
Outstanding Shares: last quarter (23.4m) vs 12m ago 1.08% < -2%
Gross Margin: 71.73% > 18% (prev 0.74%; Δ 7099 % > 0.5%)
Asset Turnover: 46.28% > 50% (prev 38.76%; Δ 7.51% > 0%)
Interest Coverage Ratio: -6.30 > 6 (EBITDA TTM -14.4m / Interest Expense TTM 5.38m)

Altman Z'' -1.35

A: 0.43 (Total Current Assets 245.9m - Total Current Liabilities 33.2m) / Total Assets 493.5m
B: -0.54 (Retained Earnings -265.1m / Total Assets 493.5m)
C: -0.07 (EBIT TTM -33.9m / Avg Total Assets 491.4m)
D: -1.86 (Book Value of Equity -268.7m / Total Liabilities 144.2m)
Altman-Z'' Score: -1.35 = CCC

Beneish M -2.86

DSRI: 1.00 (Receivables 51.3m/42.8m, Revenue 227.4m/189.7m)
GMI: 1.03 (GM 71.73% / 73.68%)
AQI: 1.09 (AQ_t 0.40 / AQ_t-1 0.37)
SGI: 1.20 (Revenue 227.4m / 189.7m)
TATA: -0.05 (NI -45.6m - CFO -19.2m) / TA 493.5m)
Beneish M-Score: -2.86 (Cap -4..+1) = A

ValueRay F-Score (Strict, 0-100) 33.07

1. Piotroski: 1.50pt
2. FCF Yield: -5.94%
3. FCF Margin: -12.94%
4. Debt/Equity: 0.28
5. Debt/Ebitda: data missing
6. ROIC - WACC: -14.29%
7. RoE: -12.97%
8. Revenue Trend: 95.35%
9. EPS Trend: -11.14%

What is the price of KIDS shares?

As of January 27, 2026, the stock is trading at USD 17.78 with a total of 82,872 shares traded.
Over the past week, the price has changed by -3.63%, over one month by +2.54%, over three months by +4.83% and over the past year by -30.60%.

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KIDS price?

Issuer Target Up/Down from current
Wallstreet Target Price 24.1 35.7%
Analysts Target Price 24.1 35.7%
ValueRay Target Price 14.1 -21%

KIDS Fundamental Data Overview January 26, 2026

P/S = 1.9971
P/B = 1.3001
Revenue TTM = 227.4m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -14.4m USD
Long Term Debt = 99.2m USD (from longTermDebt, last quarter)
Short Term Debt = 166.0k USD (from shortTermDebt, last quarter)
Debt = 99.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 495.8m USD (454.2m + Debt 99.3m - CCE 57.7m)
Interest Coverage Ratio = -6.30 (Ebit TTM -33.9m / Interest Expense TTM 5.38m)
EV/FCF = -16.84x (Enterprise Value 495.8m / FCF TTM -29.4m)
FCF Yield = -5.94% (FCF TTM -29.4m / Enterprise Value 495.8m)
FCF Margin = -12.94% (FCF TTM -29.4m / Revenue TTM 227.4m)
Net Margin = -20.06% (Net Income TTM -45.6m / Revenue TTM 227.4m)
Gross Margin = 71.73% ((Revenue TTM 227.4m - Cost of Revenue TTM 64.3m) / Revenue TTM)
Gross Margin QoQ = 73.92% (prev 72.07%)
Tobins Q-Ratio = 1.00 (Enterprise Value 495.8m / Total Assets 493.5m)
Interest Expense / Debt = 1.83% (Interest Expense 1.82m / Debt 99.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -26.8m (EBIT -33.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 245.9m / Total Current Liabilities 33.2m)
Debt / Equity = 0.28 (Debt 99.3m / totalStockholderEquity, last quarter 349.3m)
Debt / EBITDA = -5.72 (negative EBITDA) (Net Debt 82.5m / EBITDA -14.4m)
Debt / FCF = -2.80 (negative FCF - burning cash) (Net Debt 82.5m / FCF TTM -29.4m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.28% (Net Income -45.6m / Total Assets 493.5m)
RoE = -12.97% (Net Income TTM -45.6m / Total Stockholder Equity 351.6m)
RoCE = -7.53% (EBIT -33.9m / Capital Employed (Equity 351.6m + L.T.Debt 99.2m))
RoIC = -6.13% (negative operating profit) (NOPAT -26.8m / Invested Capital 437.3m)
WACC = 8.16% (E(454.2m)/V(553.5m) * Re(9.63%) + D(99.3m)/V(553.5m) * Rd(1.83%) * (1-Tc(0.21)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.43%
Fair Price DCF = unknown (Cash Flow -29.4m)
EPS Correlation: -11.14 | EPS CAGR: 0.0% | SUE: 0.09 | # QB: 0
Revenue Correlation: 95.35 | Revenue CAGR: 27.25% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.39 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.03 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+0.3% | Growth Revenue=+11.5%

Additional Sources for KIDS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle